How Investors May Respond To Marcus & Millichap (MMI) Returning to Profitability After Prior Losses

Marcus & Millichap reported its third quarter 2025 earnings, showing revenue of US$193.89 million and net income of US$0.24 million, compared to revenue of US$168.51 million and a net loss of US$5.39 ...

Should Cidara Therapeutics' (CDTX) Major CD388 Milestone and US$339 Million Funding Prompt Investor Action?

Cidara Therapeutics recently announced that its lead antiviral candidate, CD388, advanced into Phase 3 development and received FDA Breakthrough Therapy designation, with the company also securing up ...